• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

OncoHost and Dana-Farber Partner on Kidney Cancer (RCC) Biomarker Study

by Fred Pennic 06/03/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
OncoHost and Dana-Farber Partner on Kidney Cancer (RCC) Biomarker Study

What You Should Know: 

– OncoHost, a company pioneering personalized medicine approaches for better patient outcomes, announced a collaborative research study with Dana-Farber Cancer Institute, a leading cancer treatment and research center.

– The project aims to identify biomarkers in blood for renal cell carcinoma (RCC), a type of kidney cancer.

The Challenge of Personalized Treatment for RCC:

While immune-checkpoint inhibitor (ICI) therapy has revolutionized RCC treatment, these therapies can have drawbacks. They can trigger immune-related side effects and may not be effective for all patients. This research collaboration aims to address this challenge by identifying biomarkers that can predict a patient’s response to ICI therapy.

Leveraging Expertise and Resources:

The project leverages the strengths of both institutions. Dana-Farber provides a rich resource of patient plasma samples and corresponding clinical data. OncoHost will use this data to create a proteomic plasma profile of metastatic RCC patients before treatment.

The project study has several key objectives:

  • Identify protein expression changes: Researchers will associate changes in protein expression with treatment response metrics, such as overall survival, progression-free survival, and best response.
  • Predict differential responses: The study aims to develop a method to predict how patients will respond to specific treatment combinations.
  • Explore treatment pathways: Researchers will investigate the proteomic pathways associated with both treatment response and immune-related side effects. This could provide valuable insights into treatment options and resistance mechanisms.
  • Compare with other cancers: The research will compare RCC’s unique biomolecular landscape with pathways identified in the PROPHETIC trial (NCT04056247) for other cancers.

Improving RCC Treatment Outcomes:

By identifying biomarkers for RCC, this research collaboration has the potential to significantly improve treatment outcomes for kidney cancer patients. Patients will be able to receive more personalized treatment plans, potentially leading to better efficacy and reduced side effects.

"We are excited to collaborate with Dana-Farber Cancer Institute on this important research study," said Ofer Sharon, MD, CEO of OncoHost. "As we enter the era of precision medicine, validated biomarkers are increasingly used to guide treatment decisions and uncover resistance pathways in various types of tumors. However,  RCC lacks reliable biomarkers to predict ICI response. Our goal is to overcome this  challenge to improve clinical decision-making in the first line setting and, ultimately, patient outcomes."
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |